Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Pipeline Pivot | Explore Q32 Bio's strategic shift following setbacks in bempikibart trials, with focus now on ADX-097 as the key value driver for inflammatory disease treatments |
Market Reaction | Delve into the dramatic stock price decline and market cap reduction, reflecting investor concerns about Q32 Bio's narrowed pipeline and future prospects |
Financial Resilience | Learn about Q32 Bio's strong liquidity position, with a current ratio of 6.53, indicating ability to weather recent setbacks and fund ongoing research |
Future Outlook | Analyst price targets range from $9 to $22, hinging on ADX-097's Phase 2 renal basket trial results expected in early 2025, potentially reshaping company valuation |
Metrics to compare | QTTB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQTTBPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −3.8x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −4.2x | 1.6x | 2.6x | |
Price / LTM Sales | - | 15.9x | 3.1x | |
Upside (Analyst Target) | - | 181.4% | 47.8% | |
Fair Value Upside | Unlock | 12.1% | 6.9% | Unlock |